Develop and commercialize specialty pharmaceutical products in Canada. Offer Epuris (CIP-ISOTRETINOIN) for severe acne treatment. Now — the numbers.
This is an established company with proven profits.
Average growth of 24% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $2.0M would still be left in the vault — a solid cushion for hard times.
The market pays 9.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 28% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 54% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 24% a year on average.
There is $7.5M in the vault; even if every debt were paid off, $2.0M would remain.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.